ECM
PLX icon

Evergreen Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Evergreen Capital Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$372K Hold
171,338
– – 0.01% 985
2025
Q4 		$308K Hold
171,338
– – 0.01% 1017
2025
Q3 		$380K Hold
171,338
– – 0.01% 808
2025
Q2 		$254K Buy
+171,338
New +$351K 0.01% 881

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Evergreen Capital Management's PLX Position: Q1 2026 in Review

Evergreen Capital Management held its Protalix BioTherapeutics (PLX) position steady in Q1 2026 at 171,338 shares worth $372K. The position accounts for 0.01% of the portfolio, ranked #985.

Evergreen Capital Management first reported a position in PLX in Q2 2025 and has held it in 4 quarters since. The position peaked at $380K in Q3 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Evergreen Capital Management held 171,338 shares of Protalix BioTherapeutics worth $372K as of Q1 2026.
  • Evergreen Capital Management left its Protalix BioTherapeutics share count unchanged in Q1 2026.
  • Protalix BioTherapeutics made up 0.01% of Evergreen Capital Management's portfolio in Q1 2026, its #985 holding.
  • Evergreen Capital Management first reported a position in Protalix BioTherapeutics in Q2 2025 and has held it in 4 quarters since.
  • Evergreen Capital Management's Protalix BioTherapeutics position peaked at $380K in Q3 2025.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Evergreen Capital Management's 13F filing for Q1 2026, filed 14 May 2026.